ViraDx™ SARS-CoV-2/Flu A+B Rapid Antigen Test is a lateral flow immunoassay intended for the in vitro rapid, simultaneous qualitative detection and differentiation of nucleocapsid antigen from SARS-CoV-2, influenza A and influenza B directly from anterior nasal or nasopharyngeal swab specimens obtained from patients who are suspected of COVID-19 by their healthcare provider, within the first five days of onset of symptoms.

Benefits of using ViraDx

  • Efficient: 1 sample – 3 results to aid in a differential diagnosis at the point of care
  • Rapid: actionable results in 15 minutes to help improve patient management decisions during the patient visit
  • Instrument-free: user-friendly test procedure for non-lab settings
  • Accurate:1
  • COVID-19: Sensitivity 93.4%; Specificity 100%
  • Flu A: Sensitivity 91.4%; Specificity 95.7%
  • Flu B: Sensitivity 87.6%; Specificity 95.9%
Time to results 15 minutes
Sample type Anterior nasal or nasopharyngeal swab specimen
Interpretation Visually read (no instrument required)
Method Lateral flow
Storage conditions 2 to 30°C (35 to 86°)
Background Information

Influenza (flu) is a highly contagious acute viral infection of the respiratory tract. It is a communicable disease easily transmitted from person to person through aerosol droplets excreted when sneezing and coughing. There are two main types of influenza – type A and type B.2

Early differential diagnosis of influenza type A or type B can allow for proper treatment. Early diagnosis and treatment are of particular value in a clinical setting where an accurate diagnosis can assist the healthcare professional with the management of influenza patients who are at risk for complications.3

COVID-19 is an infectious disease caused by the SARS-CoV-2 virus. Similar to influenza, the virus can spread from an infected person’s mouth or nose ranging from larger respiratory droplets to smaller aerosols.4 COVID-19 symptoms can range from mild to severe.

As the early symptoms of COVID-19 are like those of seasonal influenza type A or B, a rapid, point-of-care test that can help support the differential diagnosis of COVID-19, influenza A and B is urgently needed.



  • ViraDx SARS-Cov-2/Flu A+B Rapid Antigen Test is authorized for use in Canada under Health Canada Interim Order (IO).
  • For in vitro diagnostic use.
  • Rx only.
  • ViraDx SARS-CoV-2/Flu A+B Rapid Antigen Test is not available in the United States.
  1. ViraDx [package insert] PM-169.0. Sarasota, FL: Lumos Diagnostics; 2022.
  2. Centers for Disease Control and Prevention (CDC) - Frequently Asked Influenza (Flu) Questions: 2021-2022 Season - https://www.cdc.gov/flu/about/viruses/index.htm.
  3. World Health Organization (WHO) recommendations on the use of rapid testing for influenza diagnosis, July 2005.
  4. Centers for Disease Control and Prevention (CDC) - Similarities and Differences between Flu and COVID-19​. https://www.cdc.gov/flu/symptoms/flu-vs-covid19.htm

Contact us to learn more about the ViraDx 3-in-1 rapid antigen test.

[email protected]